VExUS in Ards Patients and Association with AKI

NCT ID: NCT06805409

Last Updated: 2025-02-03

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 120 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-12-02
• Study Completion Date: 2027-12-09

Brief Summary

A single-center prospective observational study will be conducted with the aim of determining the prevalence of venous congestion during ARDS using venous Doppler and the VExUS score.

Detailed Description

Acute kidney injury (AKI) is common in patients with acute respiratory distress syndrome (ARDS) and is associated with higher mortality rates. Among the mechanisms underlying this AKI, venous congestion seems to be significant. However, methods for assessing congestion are limited and may be unreliable. The use of venous Doppler (inferior vena cava, suprahepatic veins, portal vein, and intrarenal veins) for grading the severity of congestion using the Venous Excess Ultrasound Score (VExUS) could potentially enable the earlier identification of ARDS patients with congestion.

A prospective observational monocenter study will be conducted with the objective to determine the prevalence of venous congestion during ARDS using venous Doppler and the VExUS score.

The primary outcome measure will be the proportion of patients with a VExUS score ≥ 1 within 48 hours following the initiation of invasive mechanical ventilation. The secondary objective is to evaluate the association of different VExUS grades with the occurrence of the composite endpoint of major kidney events at Day 30 (MAKE-30), defined as the occurrence of death, dependence on dialysis, or persistent elevation of creatinine ≥ 200% of baseline creatinine.

The study involves adult patients admitted to the intensive care unit with moderate to severe ARDS requiring mechanical ventilation for less than 48 hours and requiring hemodynamic support with catecholamines. Within 48 hours of initiating invasive mechanical ventilation, concurrently with the cardiac ultrasound, the multi-site venous Doppler will be performed. Demographical, clinical, and biological data will be prospectively collected. The multi-site venous Doppler will be repeated on Day 7 of mechanical ventilation initiation or during catecholamine weaning, depending on which event occurs first. Patients will be followed for the entire duration of their intensive care unit stay. For patients discharged alive from the intensive care unit, follow-up will continue until 3 months after discharge to assess the occurrence of chronic kidney disease following the initial hospitalization.

No other investigations are mandated by the protocol besides performing the multi-site venous Doppler.

Conditions

Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Patients ≥18 years old
• Moderate to severe ARDS according to the Berlin definition
• Requiring catecholamine support
• Undergoing invasive mechanical ventilation for less than 48 hours

Exclusion Criteria

• Patients presenting with acute kidney injury KDIGO III requiring renal replacement therapy before the initial ultrasound evaluation
• Requirement for veno-venous or veno-arterial ECMO circulatory support before inclusion
• Patients with end-stage chronic kidney disease, on dialysis, and/or kidney transplant recipients
• History of Child C cirrhosis and/or liver transplantation and/or portal hypertension
• History of portal thrombosis
• Known history of pulmonary hypertension
• Pregnant women
• Patients under legal protection
• Patients who have expressed opposition to participating in the research

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Armand MEKONTSO DESSAP

Créteil, Val de Marne, France

Site Status: RECRUITING

Countries

France

Central Contacts

Romain ARRESTIER, PHD

Role: CONTACT

romain.arrestier@aphp.fr

+ 33 1 45 17 85 06

Armand MEKONTSO DESSAP, MD

Role: CONTACT

romain.arrestier@aphp.fr

+ 33 1 45 17 85 06

Facility Contacts

Armand MEKONTSO DESSAP

Role: primary

armand.dessap@aphp.fr

Other Identifiers

APHP240897

Identifier Type: -

Identifier Source: org_study_id